288 related articles for article (PubMed ID: 37268331)
21. Single tube liquid biopsy for advanced non-small cell lung cancer.
de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
[TBL] [Abstract][Full Text] [Related]
22. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
23. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
24. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
25. [Advances in Clinical Application of Liquid Biopsy in Non-small Cell Lung Cancer].
Zhang M; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Oct; 24(10):723-728. PubMed ID: 34696544
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.
Beck TN; Boumber YA; Aggarwal C; Pei J; Thrash-Bingham C; Fittipaldi P; Vlasenkova R; Rao C; Borghaei H; Cristofanilli M; Mehra R; Serebriiskii I; Alpaugh RK
BMC Cancer; 2019 Jun; 19(1):603. PubMed ID: 31215484
[TBL] [Abstract][Full Text] [Related]
27. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.
Jiang N; Pan J; Fang S; Zhou C; Han Y; Chen J; Meng X; Jin X; Gong Z
Clin Chim Acta; 2019 Aug; 495():331-337. PubMed ID: 31054913
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Nagasaka M; Uddin MH; Al-Hallak MN; Rahman S; Balasubramanian S; Sukari A; Azmi AS
Mol Cancer; 2021 Jun; 20(1):82. PubMed ID: 34074295
[TBL] [Abstract][Full Text] [Related]
29. The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation.
Ren J; Liu R
Methods Mol Biol; 2023; 2695():145-163. PubMed ID: 37450117
[TBL] [Abstract][Full Text] [Related]
30. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
31. The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.
Balla A; Bhak J; Biró O
Mol Cell Probes; 2022 Dec; 66():101871. PubMed ID: 36283501
[TBL] [Abstract][Full Text] [Related]
32. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman P; Heeke S; Alix-Panabières C; Pantel K
Ann Oncol; 2019 Sep; 30(9):1448-1459. PubMed ID: 31228184
[TBL] [Abstract][Full Text] [Related]
33. EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.
Ianza A; Di Chicco A; Biagi C; Giudici F; Dicorato A; Guglielmi A; Variola F; Tomasi S; Roviello G; Generali D; Zanconati F
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2301-2307. PubMed ID: 34003366
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
Hyun MH; Lee ES; Eo JS; Kim S; Kang EJ; Sung JS; Choi YJ; Park KH; Shin SW; Lee SY; Kim YH
Lung Cancer; 2019 Aug; 134():158-166. PubMed ID: 31319975
[TBL] [Abstract][Full Text] [Related]
35. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
Shen H; Jin Y; Zhao H; Wu M; Zhang K; Wei Z; Wang X; Wang Z; Li Y; Yang F; Wang J; Chen K
BMC Med; 2022 Dec; 20(1):480. PubMed ID: 36514063
[TBL] [Abstract][Full Text] [Related]
36. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring.
Li W; Liu JB; Hou LK; Yu F; Zhang J; Wu W; Tang XM; Sun F; Lu HM; Deng J; Bai J; Li J; Wu CY; Lin QL; Lv ZW; Wang GR; Jiang GX; Ma YS; Fu D
Mol Cancer; 2022 Jan; 21(1):25. PubMed ID: 35057806
[TBL] [Abstract][Full Text] [Related]
37. Tumor-Educated Platelet RNA and Circulating Free RNA: Emerging Liquid Biopsy Markers for Different Tumor Types.
Hu H; Song H; Han B; Zhao H; He J
Front Biosci (Landmark Ed); 2024 Feb; 29(2):80. PubMed ID: 38420812
[TBL] [Abstract][Full Text] [Related]
38. Liquid biopsy: current technology and clinical applications.
Nikanjam M; Kato S; Kurzrock R
J Hematol Oncol; 2022 Sep; 15(1):131. PubMed ID: 36096847
[TBL] [Abstract][Full Text] [Related]
39. Liquid biopsy in lung cancer.
Li L; Jiang H; Zeng B; Wang X; Bao Y; Chen C; Ma L; Yuan J
Clin Chim Acta; 2024 Feb; 554():117757. PubMed ID: 38184141
[TBL] [Abstract][Full Text] [Related]
40. Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
Behel V; Chougule A; Noronha V; Patil VM; Menon N; Singh A; Chopade S; Kumar R; Shah S; More S; Banavali SD; Chandrani P; Prabhash K
Clin Lung Cancer; 2022 Jul; 23(5):410-418. PubMed ID: 35649817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
